Global Huntington’s Disease Treatment Market- Industry Analysis and Forecast (2019-2027)- By Drug Type, Treatment, End-Users, and Region.

The global Huntington’s disease treatment market was valued US$ 1.53 Bn in 2019 and is expected to reach 3.23 Bn by 2027, at a CAGR of 46.68% during a forecast period.   Global Huntington’s Disease Treatment Market To know about the Research Methodology :- Request Free Sample Report

global Huntington’s disease treatment market Introduction:

Huntington’s disease is a rare genetic condition that affects the brain and results in the degeneration of the nerve cells. It occurs between the age of 30 and 50 and worsens with time. The disorder usually becomes fatal after 20 years of its occurrence. The symptoms of the targeted disorder include depression, mood swings, amnesia, involuntary movement, and weight loss. It is associated with Parkinson’s disease and Alzheimer’s as well as other health complications. Huntington’s disease can be diagnosed through CT scans and MRIs. The report study has analyzed the revenue impact of COVID-19 pandemic on the sales revenue of market leaders, market followers, and disrupters in the report, and the same is reflected in our analysis.

global Huntington’s disease treatment market Drivers and Restraints:

Growth and advancement in the treatment process and machinery used to treat such disease are the leading factors for market growth. On-going scientific research responsible for awareness about Huntington’s disease amongst the population is considered as one of the major factors driving the growth of Huntington’s disease therapeutics market. Medical needs across the globe are seeking the attention of scientists and researchers to develop a therapy for Huntington’s disease. Furthermore, high investment by the pharmaceutical companies involved in the R&D sector to develop innovative and curative drugs for the disease is fuelling the growth of the global HD treatment market as there is no proper treatment available. Besides, the presence of alternative therapies, including speech therapy, psychotherapy, and physiotherapy strongly contributed and increased the potential of the market growth for Huntington’s disease therapeutics. However, due to the presence of stringent regulation and policies, the number of approved drugs is limited, hampering the availability of the drug in the market whereby, hindering the market growth in the coming years.

Huntington’s Disease Treatment Market Segment analysis:

Based on the drug type segment, tetrabenazine is expected to dominate the overall market demand in the coming forecast as it is the only drug approved by the US FDA for the treatment of chorea in Huntington’s disease. Tetrabenazine provides significant benefits in the treatment of chorea associated with HD. Health-care providers need to screen patients carefully before initiating treatment with this medication due to the adverse effects of tetrabenazine. In the future, additional long-term and comparative studies would be useful for further clarification of the role of tetrabenazine in the treatment of HD-associated chorea. According to IQVIA, US sales of tetrabenazine tablets 12.5 mg and 25 mg were ~$ 0.119 Bn in the year 2019, projected to show significant growth during the forecasted period.

Huntington’s Disease Treatment Market Regional Analysis:

Regionally, North America is expected to dominate Huntington’s disease treatment market, the US is the major contributor with a reported market share of ~ 65.59% in the base year and is estimated to show steady growth during the forecasted period. The on-going R&D activities and investment by pharmaceutical companies in the region are projected to run the innovation of highly effective and improved drugs for the treatment of Huntington’s disorder. Furthermore, advancement in technology and the presence of numerous vendors based on small and large sales are majorly participating to invest in this market will boost the market growth in the coming years. On the other hand, Europe is expected to show substantial market growth owing to its economic stability. Europe is estimated to hold the second-largest share in the market owing to the growing aging population along with rising research and development activities aiming at Huntington’s disease in the region. The objective of the report is to present a comprehensive analysis of the Global Huntington’s Disease Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

Recent Advances in the Treatment of Huntington’s Disease: Targeting DNA and RNA:

Recent developments in gene therapy, including antisense oligonucleotides, small interfering RNAs, and gene editing are bringing new hope to the Huntington’s community. This step is expected to contribute to the market growth on another level in terms of value. The report also helps in understanding Global Huntington’s Disease Treatment Market dynamics, structure by analysing the market segments and project the Global Huntington’s Disease Treatment Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Huntington’s Disease Treatment Market make the report investor’s guide.

Scope of Huntington’s Disease Treatment Market: Inquire before buying

Global Huntington’s Disease Treatment Market, By Drug Type

• Tetrabenazine • Antidepressants • Antipsychotic Drugs • Tranquilizers • Others

Global Huntington’s Disease Treatment Market, By Treatment

• Symptomatic therapy • Disease-modifying therapy

Global Huntington’s Disease Treatment Market, By End-Users

• Hospital • Clinics • Online Pharmacies • Retail Pharmacies • Others

Global Huntington’s Disease Treatment Market, By Region

• North America • Europe • Asia Pacific • Latin America • Middle East & Africa

Key Players Operating the Huntington’s Disease Treatment Market

• Alnylam Pharmaceuticals Inc • AmpliPhi Biosciences Corp • Ceregene Inc • Lundbeck • Prana Biotechnology Limited • Teva Pharmaceutical Industries Ltd • Cortex Pharmaceuticals Inc • Vertex Pharmaceuticals Incorporated • Auspex Pharmaceuticals • SOM Biotech • GlaxoSmithKline • Siena Biotech • Raptor Pharmaceutical • Pfizer • Palobiofarma • Omeros • Ipsen • Valeant Pharmaceuticals International Inc
Global Huntington’s Disease Treatment Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Huntington’s Disease Treatment Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Huntington’s Disease Treatment Market Analysis and Forecast 6.1. Huntington’s Disease Treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Huntington’s Disease Treatment Market Analysis and Forecast, By Drug Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Huntington’s Disease Treatment Market Value Share Analysis, By Drug Type 7.4. Huntington’s Disease Treatment Market Size (US$ Bn) Forecast, By Drug Type 7.5. Huntington’s Disease Treatment Market Analysis, By Drug Type 7.6. Huntington’s Disease Treatment Market Attractiveness Analysis, By Drug Type 8. Huntington’s Disease Treatment Market Analysis and Forecast, By Treatment 8.1. Introduction and Definition 8.2. Key Findings 8.3. Huntington’s Disease Treatment Market Value Share Analysis, By Treatment 8.4. Huntington’s Disease Treatment Market Size (US$ Bn) Forecast, By Treatment 8.5. Huntington’s Disease Treatment Market Analysis, By Treatment 8.6. Huntington’s Disease Treatment Market Attractiveness Analysis, By Treatment 9. Huntington’s Disease Treatment Market Analysis and Forecast, By End-Users 9.1. Introduction and Definition 9.2. Key Findings 9.3. Huntington’s Disease Treatment Market Value Share Analysis, By End-Users 9.4. Huntington’s Disease Treatment Market Size (US$ Bn) Forecast, By End-Users 9.5. Huntington’s Disease Treatment Market Analysis, By End-Users 9.6. Huntington’s Disease Treatment Market Attractiveness Analysis, By End-Users 10. Huntington’s Disease Treatment Market Analysis, by Region 10.1. Huntington’s Disease Treatment Market Value Share Analysis, by Region 10.2. Huntington’s Disease Treatment Market Size (US$ Bn) Forecast, by Region 10.3. Huntington’s Disease Treatment Market Attractiveness Analysis, by Region 11. North America Huntington’s Disease Treatment Market Analysis 11.1. Key Findings 11.2. North America Huntington’s Disease Treatment Market Overview 11.3. North America Huntington’s Disease Treatment Market Value Share Analysis, By Drug Type 11.4. North America Huntington’s Disease Treatment Market Forecast, By Drug Type 11.4.1. Tetrabenazine 11.4.2. Antidepressants 11.4.3. Antipsychotic Drugs 11.4.4. Tranquilizers 11.4.5. Others 11.5. North America Huntington’s Disease Treatment Market Value Share Analysis, By Treatment 11.6. North America Huntington’s Disease Treatment Market Forecast, By Treatment 11.6.1. Symptomatic therapy 11.6.2. Disease-modifying therapy 11.7. North America Huntington’s Disease Treatment Market Value Share Analysis, By End-Users 11.8. North America Huntington’s Disease Treatment Market Forecast, By End-Users 11.8.1. Hospital 11.8.2. Clinics 11.8.3. Online Pharmacies 11.8.4. Retail Pharmacies 11.8.5. Others 11.9. North America Huntington’s Disease Treatment Market Value Share Analysis, by Country 11.10. North America Huntington’s Disease Treatment Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Huntington’s Disease Treatment Market Analysis, by Country 11.12. U.S. Huntington’s Disease Treatment Market Forecast, By Drug Type 11.12.1. Tetrabenazine 11.12.2. Antidepressants 11.12.3. Antipsychotic Drugs 11.12.4. Tranquilizers 11.12.5. Others 11.13. U.S. Huntington’s Disease Treatment Market Forecast, By Treatment 11.13.1. Symptomatic therapy 11.13.2. Disease-modifying therapy 11.14. U.S. Huntington’s Disease Treatment Market Forecast, By End-Users 11.14.1. Hospital 11.14.2. Clinics 11.14.3. Online Pharmacies 11.14.4. Retail Pharmacies 11.14.5. Others 11.15. Canada Huntington’s Disease Treatment Market Forecast, By Drug Type 11.15.1. Tetrabenazine 11.15.2. Antidepressants 11.15.3. Antipsychotic Drugs 11.15.4. Tranquilizers 11.15.5. Others 11.16. Steel Canada Huntington’s Disease Treatment Market Forecast, By Treatment 11.16.1. Symptomatic therapy 11.16.2. Disease-modifying therapy 11.17. Canada Huntington’s Disease Treatment Market Forecast, By End-Users 11.17.1. Hospital 11.17.2. Clinics 11.17.3. Online Pharmacies 11.17.4. Retail Pharmacies 11.17.5. Others 11.18. North America Huntington’s Disease Treatment Market Attractiveness Analysis 11.18.1. By Drug Type 11.18.2. By Treatment 11.18.3. By End-Users 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Huntington’s Disease Treatment Market Analysis 12.1. Key Findings 12.2. Europe Huntington’s Disease Treatment Market Overview 12.3. Europe Huntington’s Disease Treatment Market Value Share Analysis, By Drug Type 12.4. Europe Huntington’s Disease Treatment Market Forecast, By Drug Type 12.4.1. Tetrabenazine 12.4.2. Antidepressants 12.4.3. Antipsychotic Drugs 12.4.4. Tranquilizers 12.4.5. Others 12.5. Europe Huntington’s Disease Treatment Market Value Share Analysis, By Treatment 12.6. Europe Huntington’s Disease Treatment Market Forecast, By Treatment 12.6.1. Symptomatic therapy 12.6.2. Disease-modifying therapy 12.7. Europe Huntington’s Disease Treatment Market Value Share Analysis, By End-Users 12.8. Europe Huntington’s Disease Treatment Market Forecast, By End-Users 12.8.1. Hospital 12.8.2. Clinics 12.8.3. Online Pharmacies 12.8.4. Retail Pharmacies 12.8.5. Others 12.9. Europe Huntington’s Disease Treatment Market Value Share Analysis, by Country 12.10. Europe Huntington’s Disease Treatment Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Huntington’s Disease Treatment Market Analysis, by Country 12.12. Germany Huntington’s Disease Treatment Market Forecast, By Drug Type 12.12.1. Tetrabenazine 12.12.2. Antidepressants 12.12.3. Antipsychotic Drugs 12.12.4. Tranquilizers 12.12.5. Others 12.13. Germany Huntington’s Disease Treatment Market Forecast, By Treatment 12.13.1. Symptomatic therapy 12.13.2. Disease-modifying therapy 12.14. Germany Huntington’s Disease Treatment Market Forecast, By End-Users 12.14.1. Hospital 12.14.2. Clinics 12.14.3. Online Pharmacies 12.14.4. Retail Pharmacies 12.14.5. Others 12.15. U.K. Huntington’s Disease Treatment Market Forecast, By Drug Type 12.15.1. Tetrabenazine 12.15.2. Antidepressants 12.15.3. Antipsychotic Drugs 12.15.4. Tranquilizers 12.15.5. Others 12.16. U.K. Huntington’s Disease Treatment Market Forecast, By Treatment 12.16.1. Symptomatic therapy 12.16.2. Disease-modifying therapy 12.17. U.K. Huntington’s Disease Treatment Market Forecast, By End-Users 12.17.1. Hospital 12.17.2. Clinics 12.17.3. Online Pharmacies 12.17.4. Retail Pharmacies 12.17.5. Others 12.18. France Huntington’s Disease Treatment Market Forecast, By Drug Type 12.18.1. Tetrabenazine 12.18.2. Antidepressants 12.18.3. Antipsychotic Drugs 12.18.4. Tranquilizers 12.18.5. Others 12.19. France Huntington’s Disease Treatment Market Forecast, By Treatment 12.19.1. Symptomatic therapy 12.19.2. Disease-modifying therapy 12.20. France Huntington’s Disease Treatment Market Forecast, By End-Users 12.20.1. Hospital 12.20.2. Clinics 12.20.3. Online Pharmacies 12.20.4. Retail Pharmacies 12.20.5. Others 12.21. Italy Huntington’s Disease Treatment Market Forecast, By Drug Type 12.21.1. Tetrabenazine 12.21.2. Antidepressants 12.21.3. Antipsychotic Drugs 12.21.4. Tranquilizers 12.21.5. Others 12.22. Italy Huntington’s Disease Treatment Market Forecast, By Treatment 12.22.1. Symptomatic therapy 12.22.2. Disease-modifying therapy 12.23. Italy Huntington’s Disease Treatment Market Forecast, By End-Users 12.23.1. Hospital 12.23.2. Clinics 12.23.3. Online Pharmacies 12.23.4. Retail Pharmacies 12.23.5. Others 12.24. Spain Huntington’s Disease Treatment Market Forecast, By Drug Type 12.24.1. Tetrabenazine 12.24.2. Antidepressants 12.24.3. Antipsychotic Drugs 12.24.4. Tranquilizers 12.24.5. Others 12.25. Spain Huntington’s Disease Treatment Market Forecast, By Treatment 12.25.1. Symptomatic therapy 12.25.2. Disease-modifying therapy 12.26. Spain Huntington’s Disease Treatment Market Forecast, By End-Users 12.26.1. Hospital 12.26.2. Clinics 12.26.3. Online Pharmacies 12.26.4. Retail Pharmacies 12.26.5. Others 12.27. Rest of Europe Huntington’s Disease Treatment Market Forecast, By Drug Type 12.27.1. Tetrabenazine 12.27.2. Antidepressants 12.27.3. Antipsychotic Drugs 12.27.4. Tranquilizers 12.27.5. Others 12.28. Rest of Europe Huntington’s Disease Treatment Market Forecast, By Treatment 12.28.1. Symptomatic therapy 12.28.2. Disease-modifying therapy 12.29. Rest of Europe Huntington’s Disease Treatment Market Forecast, By End-Users 12.29.1. Hospital 12.29.2. Clinics 12.29.3. Online Pharmacies 12.29.4. Retail Pharmacies 12.29.5. Others 12.30. Europe Huntington’s Disease Treatment Market Attractiveness Analysis 12.30.1. By Drug Type 12.30.2. By Treatment 12.30.3. By End-Users 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Huntington’s Disease Treatment Market Analysis 13.1. Key Findings 13.2. Asia Pacific Huntington’s Disease Treatment Market Overview 13.3. Asia Pacific Huntington’s Disease Treatment Market Value Share Analysis, By Drug Type 13.4. Asia Pacific Huntington’s Disease Treatment Market Forecast, By Drug Type 13.4.1. Tetrabenazine 13.4.2. Antidepressants 13.4.3. Antipsychotic Drugs 13.4.4. Tranquilizers 13.4.5. Others 13.5. Asia Pacific Huntington’s Disease Treatment Market Value Share Analysis, By Treatment 13.6. Asia Pacific Huntington’s Disease Treatment Market Forecast, By Treatment 13.6.1. Symptomatic therapy 13.6.2. Disease-modifying therapy 13.7. Asia Pacific Huntington’s Disease Treatment Market Value Share Analysis, By End-Users 13.8. Asia Pacific Huntington’s Disease Treatment Market Forecast, By End-Users 13.8.1. Hospital 13.8.2. Clinics 13.8.3. Online Pharmacies 13.8.4. Retail Pharmacies 13.8.5. Others 13.9. Asia Pacific Huntington’s Disease Treatment Market Value Share Analysis, by Country 13.10. Asia Pacific Huntington’s Disease Treatment Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Huntington’s Disease Treatment Market Analysis, by Country 13.12. China Huntington’s Disease Treatment Market Forecast, By Drug Type 13.12.1. Tetrabenazine 13.12.2. Antidepressants 13.12.3. Antipsychotic Drugs 13.12.4. Tranquilizers 13.12.5. Others 13.13. China Huntington’s Disease Treatment Market Forecast, By Treatment 13.13.1. Symptomatic therapy 13.13.2. Disease-modifying therapy 13.14. China Huntington’s Disease Treatment Market Forecast, By End-Users 13.14.1. Hospital 13.14.2. Clinics 13.14.3. Online Pharmacies 13.14.4. Retail Pharmacies 13.14.5. Others 13.15. India Huntington’s Disease Treatment Market Forecast, By Drug Type 13.15.1. Tetrabenazine 13.15.2. Antidepressants 13.15.3. Antipsychotic Drugs 13.15.4. Tranquilizers 13.15.5. Others 13.16. India Huntington’s Disease Treatment Market Forecast, By Treatment 13.16.1. Symptomatic therapy 13.16.2. Disease-modifying therapy 13.17. India Huntington’s Disease Treatment Market Forecast, By End-Users 13.17.1. Hospital 13.17.2. Clinics 13.17.3. Online Pharmacies 13.17.4. Retail Pharmacies 13.17.5. Others 13.18. Japan Huntington’s Disease Treatment Market Forecast, By Drug Type 13.18.1. Tetrabenazine 13.18.2. Antidepressants 13.18.3. Antipsychotic Drugs 13.18.4. Tranquilizers 13.18.5. Others 13.19. Japan Huntington’s Disease Treatment Market Forecast, By Treatment 13.19.1. Symptomatic therapy 13.19.2. Disease-modifying therapy 13.20. Japan Huntington’s Disease Treatment Market Forecast, By End-Users 13.20.1. Hospital 13.20.2. Clinics 13.20.3. Online Pharmacies 13.20.4. Retail Pharmacies 13.20.5. Others 13.21. ASEAN Huntington’s Disease Treatment Market Forecast, By Drug Type 13.21.1. Tetrabenazine 13.21.2. Antidepressants 13.21.3. Antipsychotic Drugs 13.21.4. Tranquilizers 13.21.5. Others 13.22. ASEAN Huntington’s Disease Treatment Market Forecast, By Treatment 13.22.1. Symptomatic therapy 13.22.2. Disease-modifying therapy 13.23. ASEAN Huntington’s Disease Treatment Market Forecast, By End-Users 13.23.1. Hospital 13.23.2. Clinics 13.23.3. Online Pharmacies 13.23.4. Retail Pharmacies 13.23.5. Others 13.24. Rest of Asia Pacific Huntington’s Disease Treatment Market Forecast, By Drug Type 13.24.1. Tetrabenazine 13.24.2. Antidepressants 13.24.3. Antipsychotic Drugs 13.24.4. Tranquilizers 13.24.5. Others 13.25. Rest of Asia Pacific Huntington’s Disease Treatment Market Forecast, By Treatment 13.25.1. Symptomatic therapy 13.25.2. Disease-modifying therapy 13.26. Rest of Asia Pacific Huntington’s Disease Treatment Market Forecast, By End-Users 13.26.1. Hospital 13.26.2. Clinics 13.26.3. Online Pharmacies 13.26.4. Retail Pharmacies 13.26.5. Others 13.27. Asia Pacific Huntington’s Disease Treatment Market Attractiveness Analysis 13.27.1. By Drug Type 13.27.2. By Treatment 13.27.3. By End-Users 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Huntington’s Disease Treatment Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Huntington’s Disease Treatment Market Overview 14.3. Middle East & Africa Huntington’s Disease Treatment Market Value Share Analysis, By Drug Type 14.4. Middle East & Africa Huntington’s Disease Treatment Market Forecast, By Drug Type 14.4.1. Tetrabenazine 14.4.2. Antidepressants 14.4.3. Antipsychotic Drugs 14.4.4. Tranquilizers 14.4.5. Others 14.5. Middle East & Africa Huntington’s Disease Treatment Market Value Share Analysis, By Treatment 14.6. Middle East & Africa Huntington’s Disease Treatment Market Forecast, By Treatment 14.6.1. Symptomatic therapy 14.6.2. Disease-modifying therapy 14.7. Middle East & Africa Huntington’s Disease Treatment Market Value Share Analysis, By End-Users 14.8. Middle East & Africa Huntington’s Disease Treatment Market Forecast, By End-Users 14.8.1. Hospital 14.8.2. Clinics 14.8.3. Online Pharmacies 14.8.4. Retail Pharmacies 14.8.5. Others 14.9. Middle East & Africa Huntington’s Disease Treatment Market Value Share Analysis, by Country 14.10. Middle East & Africa Huntington’s Disease Treatment Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Huntington’s Disease Treatment Market Analysis, by Country 14.12. GCC Huntington’s Disease Treatment Market Forecast, By Drug Type 14.12.1. Tetrabenazine 14.12.2. Antidepressants 14.12.3. Antipsychotic Drugs 14.12.4. Tranquilizers 14.12.5. Others 14.13. GCC Huntington’s Disease Treatment Market Forecast, By Treatment 14.13.1. Symptomatic therapy 14.13.2. Disease-modifying therapy 14.14. GCC Huntington’s Disease Treatment Market Forecast, By End-Users 14.14.1. Hospital 14.14.2. Clinics 14.14.3. Online Pharmacies 14.14.4. Retail Pharmacies 14.14.5. Others 14.15. South Africa Huntington’s Disease Treatment Market Forecast, By Drug Type 14.15.1. Tetrabenazine 14.15.2. Antidepressants 14.15.3. Antipsychotic Drugs 14.15.4. Tranquilizers 14.15.5. Others 14.16. South Africa Huntington’s Disease Treatment Market Forecast, By Treatment 14.16.1. Symptomatic therapy 14.16.2. Disease-modifying therapy 14.17. South Africa Huntington’s Disease Treatment Market Forecast, By End-Users 14.17.1. Hospital 14.17.2. Clinics 14.17.3. Online Pharmacies 14.17.4. Retail Pharmacies 14.17.5. Others 14.18. Rest of Middle East & Africa Huntington’s Disease Treatment Market Forecast, By Drug Type 14.18.1. Tetrabenazine 14.18.2. Antidepressants 14.18.3. Antipsychotic Drugs 14.18.4. Tranquilizers 14.18.5. Others 14.19. Rest of Middle East & Africa Huntington’s Disease Treatment Market Forecast, By Treatment 14.19.1. Symptomatic therapy 14.19.2. Disease-modifying therapy 14.20. Rest of Middle East & Africa Huntington’s Disease Treatment Market Forecast, By End-Users 14.20.1. Hospital 14.20.2. Others 14.21. Middle East & Africa Huntington’s Disease Treatment Market Attractiveness Analysis 14.21.1. By Drug Type 14.21.2. By Treatment 14.21.3. By End-Users 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Huntington’s Disease Treatment Market Analysis 15.1. Key Findings 15.2. South America Huntington’s Disease Treatment Market Overview 15.3. South America Huntington’s Disease Treatment Market Value Share Analysis, By Drug Type 15.4. South America Huntington’s Disease Treatment Market Forecast, By Drug Type 15.4.1. Tetrabenazine 15.4.2. Antidepressants 15.4.3. Antipsychotic Drugs 15.4.4. Tranquilizers 15.4.5. Others 15.5. South America Huntington’s Disease Treatment Market Value Share Analysis, By Treatment 15.6. South America Huntington’s Disease Treatment Market Forecast, By Treatment 15.6.1. Symptomatic therapy 15.6.2. Disease-modifying therapy 15.7. South America Huntington’s Disease Treatment Market Value Share Analysis, By End-Users 15.8. South America Huntington’s Disease Treatment Market Forecast, By End-Users 15.8.1. Hospital 15.8.2. Clinics 15.8.3. Online Pharmacies 15.8.4. Retail Pharmacies 15.8.5. Others 15.9. South America Huntington’s Disease Treatment Market Value Share Analysis, by Country 15.10. South America Huntington’s Disease Treatment Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Huntington’s Disease Treatment Market Analysis, by Country 15.12. Brazil Huntington’s Disease Treatment Market Forecast, By Drug Type 15.12.1. Tetrabenazine 15.12.2. Antidepressants 15.12.3. Antipsychotic Drugs 15.12.4. Tranquilizers 15.12.5. Others 15.13. Brazil Huntington’s Disease Treatment Market Forecast, By Treatment 15.13.1. Symptomatic therapy 15.13.2. Disease-modifying therapy 15.14. Brazil Huntington’s Disease Treatment Market Forecast, By End-Users 15.14.1. Hospital 15.14.2. Clinics 15.14.3. Online Pharmacies 15.14.4. Retail Pharmacies 15.14.5. Others 15.15. Mexico Huntington’s Disease Treatment Market Forecast, By Drug Type 15.15.1. Tetrabenazine 15.15.2. Antidepressants 15.15.3. Antipsychotic Drugs 15.15.4. Tranquilizers 15.15.5. Others 15.16. Mexico Huntington’s Disease Treatment Market Forecast, By Treatment 15.16.1. Symptomatic therapy 15.16.2. Disease-modifying therapy 15.17. Mexico Huntington’s Disease Treatment Market Forecast, By End-Users 15.17.1. Hospital 15.17.2. Clinics 15.17.3. Online Pharmacies 15.17.4. Retail Pharmacies 15.17.5. Others 15.18. Rest of South America Huntington’s Disease Treatment Market Forecast, By Drug Type 15.18.1. Tetrabenazine 15.18.2. Antidepressants 15.18.3. Antipsychotic Drugs 15.18.4. Tranquilizers 15.18.5. Others 15.19. Rest of South America Huntington’s Disease Treatment Market Forecast, By Treatment 15.19.1. Symptomatic therapy 15.19.2. Disease-modifying therapy 15.20. Rest of South America Huntington’s Disease Treatment Market Forecast, By End-Users 15.20.1. Hospital 15.20.2. Clinics 15.20.3. Online Pharmacies 15.20.4. Retail Pharmacies 15.20.5. Others 15.21. South America Huntington’s Disease Treatment Market Attractiveness Analysis 15.21.1. By Drug Type 15.21.2. By Treatment 15.21.3. By End-Users 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications, and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Alnylam Pharmaceuticals Inc 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. AmpliPhi Biosciences Corp 16.3.3. Ceregene Inc 16.3.4. Lundbeck 16.3.5. Prana Biotechnology Limited 16.3.6. Teva Pharmaceutical Industries Ltd 16.3.7. Cortex Pharmaceuticals Inc 16.3.8. Vertex Pharmaceuticals Incorporated 16.3.9. Auspex Pharmaceuticals 16.3.10. SOM Biotech 16.3.11. GlaxoSmithKline 16.3.12. Siena Biotech 16.3.13. Raptor Pharmaceutical 16.3.14. Pfizer 16.3.15. Palobiofarma 16.3.16. Omeros 16.3.17. Ipsen 16.3.18. Valeant Pharmaceuticals International Inc 17. Primary Key Insights

About This Report

Report ID 65831
Category Healthcare
Published Date July 2020
Updated Date
Contact Us